Hanall Biopharma (009420)

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson’s disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves’ disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.